MXPA03007653A - Uso de lp82 para tratar trastornos hematopoyeticos. - Google Patents

Uso de lp82 para tratar trastornos hematopoyeticos.

Info

Publication number
MXPA03007653A
MXPA03007653A MXPA03007653A MXPA03007653A MXPA03007653A MX PA03007653 A MXPA03007653 A MX PA03007653A MX PA03007653 A MXPA03007653 A MX PA03007653A MX PA03007653 A MXPA03007653 A MX PA03007653A MX PA03007653 A MXPA03007653 A MX PA03007653A
Authority
MX
Mexico
Prior art keywords
hematopoietic disorders
treat hematopoietic
treat
disorders
hematopoietic
Prior art date
Application number
MXPA03007653A
Other languages
English (en)
Inventor
Ling Liu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA03007653A publication Critical patent/MXPA03007653A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
MXPA03007653A 2001-02-28 2002-02-14 Uso de lp82 para tratar trastornos hematopoyeticos. MXPA03007653A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27224201P 2001-02-28 2001-02-28
US33274001P 2001-11-19 2001-11-19
US35378902P 2002-02-01 2002-02-01
PCT/US2002/003377 WO2002070001A2 (en) 2001-02-28 2002-02-14 Use of lp82 to treat hematopoietic disorders

Publications (1)

Publication Number Publication Date
MXPA03007653A true MXPA03007653A (es) 2003-12-04

Family

ID=27402462

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007653A MXPA03007653A (es) 2001-02-28 2002-02-14 Uso de lp82 para tratar trastornos hematopoyeticos.

Country Status (7)

Country Link
US (1) US7101539B2 (es)
EP (1) EP1383531A2 (es)
JP (1) JP2005506287A (es)
CN (1) CN1503677A (es)
CA (1) CA2433933A1 (es)
MX (1) MXPA03007653A (es)
WO (1) WO2002070001A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5015404B2 (ja) 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド 可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
JP4908723B2 (ja) 2000-09-15 2012-04-04 ザイモジェネティクス， インコーポレイテッド 炎症を治療するための方法
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
WO2003051384A1 (en) 2001-12-17 2003-06-26 Zymogenetics, Inc. Method for treating cervical cancer
US7994125B2 (en) * 2003-02-14 2011-08-09 Istituto Superiore Di Sanita Stem cell factor for preventing chemotherapy-induced depletion of blood cells
DK1606317T3 (da) 2003-03-24 2010-10-25 Zymogenetics Inc Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
EP1653995A1 (en) * 2003-08-08 2006-05-10 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
WO2005052000A2 (en) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
CN101198625A (zh) 2004-10-22 2008-06-11 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣及其在炎症中的使用方法
RS61082B1 (sr) 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
WO2017095788A1 (en) * 2015-11-30 2017-06-08 The General Hospital Corporation Treatment with angiogenin to enhance hematopoietic reconstitution
CN111228467A (zh) * 2020-03-11 2020-06-05 白晓春 白介素19在制备治疗中性粒细胞减少症药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739420B2 (en) * 1997-11-26 2001-10-11 Zymogenetics Inc. Mammalian cytokine-like polypeptide-10
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
CA2339043A1 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20

Also Published As

Publication number Publication date
CA2433933A1 (en) 2002-09-12
US20040092445A1 (en) 2004-05-13
EP1383531A2 (en) 2004-01-28
CN1503677A (zh) 2004-06-09
WO2002070001A2 (en) 2002-09-12
JP2005506287A (ja) 2005-03-03
WO2002070001A3 (en) 2003-02-06
US7101539B2 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
IL159771A0 (en) Combinations for the treatment of inflammatory disorders
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
EP1385937A4 (en) CONTRIBUTION OF POLYNUCLEOTIDE AGENTS TO THE CENTRAL NERVOUS SYSTEM
EP1390029A4 (en) PHENYLINDOLES FOR THE TREATMENT OF HIV INFECTION
GB0111186D0 (en) Novel compounds
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
MXPA03008634A (es) Nuevos compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
IL155433A0 (en) Treatment of t cell disorders
MXPA03003592A (es) Uso de la tolerancia en el tratamiento del asma.
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
HK1066022A1 (en) Use of 1,1,1,3,3-pentafluorobutan
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
AU4838301A (en) Treatment of disorders relating to the serotonergic system
AU2003224720A8 (en) Use of resistin to treat hematopoietic disorders
ZA200205415B (en) Novel therapeutic use of enoxaparin.
TW461552U (en) Improvement of seven-string ancient lute
AU2002211600A1 (en) Gene expression profiling of antidepressant action in the brain
GB0010496D0 (en) Treatment of conditions of the central nervous system
HUP0301798A3 (en) Treatment of eating disorders using carboxyalkylethers
GB0003228D0 (en) Treatment of GI disorders
WO2002055064A3 (en) Mucopolysaccharidosis therapies